US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anti-Pandemic Concept

1,341.13

-8.1082-0.60%

Number of Gainers:7

Number of Losers:13

Number of Flat:- -

PE:- -

High:1,349.81

Open:1,349.81

Low:1,326.47

Close:1,349.23

Loading ...

Loeb's Third Point builds stake in Band-Aid maker Kenvue

Moderna (MRNA) Stock Falls Amid Market Uptick: What Investors Need to Know

Market Chatter: Novavax Asked by FDA to Run Additional Trial on COVID-19 Vaccine

MT Newswires Live

BUZZ-Novavax falls after report FDA demands new trial for COVID vaccine

Moderna Shares Lose Ground With Volume Spick in Late Afternoon, Last Down 2%; Pfizer Shares Lose Some Steam, Last up 0.6%

THOMSON REUTERS

FDA asks Novavax to complete new clinical trial for delayed COVID-19 shot, WSJ reports

Novavax asked for new Covid-19 vaccine trial by FDA, WSJ reports

Novavax asked by FDA to complete additional COVID trial, WSJ says

BRIEF-FDA Asks Vaccine Maker Novavax To Complete New Clinical Trial For Delayed Covid-19 Shot - WSJ

FDA Asks Vaccine Maker Novavax to Complete New Clinical Trial for Delayed Covid-19 Shot - WSJ

THOMSON REUTERS

Tariffs Cast a Shadow on Abbott's 2025 View: Time to Sell ABT Stock?

Moderna (NasdaqGS:MRNA) Sees 11% Share Price Surge Over Last Week

Simply Wall St.

Gilead Shares Down 3.6% After Quarterly Revenue Miss

THOMSON REUTERS

Johnson & Johnson (JNJ) Soared as Markets Favored Defensive Sector

Wall Street Analysts Are Bullish on Top Healthcare Picks

Gilead Shares Down 4.2% Premarket After Quarterly Revenue Miss

THOMSON REUTERS

Gilead : RBC Raises Target Price to $92 From $89

THOMSON REUTERS

Gilead Sciences (GILD) Gets a Buy from Oppenheimer

Director Makes Significant Move with Alpha Pro Tech Stock Sale!

Shionogi Raises Year-End Dividend Forecast to 33 Yen

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4568/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"Anti-Pandemic Concept","latestPrice":1341.1263,"timestamp":1745611199999,"preClose":1349.2345,"halted":0,"volume":105403296,"delay":0,"changeRate":-0.006009,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-8.108154,"latestTime":"04-25 16:00:00 EDT","open":1349.8055,"high":1349.8055,"low":1326.4735,"amount":5679459236.570498,"amplitude":0.017293,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745827200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.624317,"peRate":21.905145,"turnoverRate":0.006797,"increases":7,"decrements":13,"flats":0,"marketCap":1107563323728.5,"floatMarketCap":1088066496974.5},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1349.8055,"amplitude":0.017293,"preClose":1349.2345,"low":1326.4735,"pbRate":"3.624317","latestPrice":1341.1263,"volume":105403296,"delay":0,"open":1349.8055,"prevYearClose":1274.8187,"prevWeekClose":1341.7848,"prevMonthClose":1427.887,"prevQuarterClose":1427.887,"fiveDayClose":1341.7848,"twentyDayClose":1413.7192,"sixtyDayClose":1349.6512,"secType":"PLATE","market":"US","turnoverRate":0.006797,"peRate":21.905145,"marketCap":1107563323728.5,"floatMarketCap":1088066496974.5,"timestamp":1745611199999,"nameCN":"Anti-Pandemic Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":7,"down":13,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530196435","title":"Loeb's Third Point builds stake in Band-Aid maker Kenvue","url":"https://stock-news.laohu8.com/highlight/detail?id=2530196435","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530196435?lang=en_us&edition=fundamental","pubTime":"2025-04-26 06:08","pubTimestamp":1745618938,"startTime":"0","endTime":"0","summary":"Loeb's Third Point builds stake in Band-Aid maker KenvueBy Svea Herbst-BaylissNEW YORK, April 25 (Reuters) - Billionaire investor Daniel Loeb's hedge fund Third Point is building a stake in Kenvue KVU","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nL1N3R319V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","IE0002141913.USD","LU0114720955.EUR","LU1280957306.USD","SG9999002224.SGD","LU1506573853.SGD","LU0070302665.USD","LU1914381329.SGD","JNJ","LU1196500208.SGD","LU1778281490.HKD","IE0002270589.USD","LU1732800096.USD","LU1267930573.SGD","LU0786609619.USD","IE00B42XCP33.USD","BK4007","LU1066051811.HKD","LU1066053197.SGD","BBWI","LU2430703178.SGD","LU1244550221.USD","BK4559","IE00BFXG1179.USD","SG9999015978.USD","LU0061475181.USD","AAP","LU1732799900.SGD","LU2129689514.USD","BK4214","LU2505996509.AUD","LU1221951129.SGD","LU2430703251.USD","IE00BDGV0183.EUR","BK4524","LU0208291251.USD","LU1244550494.USD","LU2430703095.HKD","LU1244550577.SGD","LU1929549753.HKD","SG9999015945.SGD","LU1935042991.SGD","IE00BBT3K403.USD","KVUE","BK4568","LU0795875086.SGD","BK4183","LU0310800379.SGD","LU0345769128.USD"],"gpt_icon":1},{"id":"2530956192","title":"Moderna (MRNA) Stock Falls Amid Market Uptick: What Investors Need to Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2530956192","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530956192?lang=en_us&edition=fundamental","pubTime":"2025-04-26 05:50","pubTimestamp":1745617814,"startTime":"0","endTime":"0","summary":"In the latest trading session, Moderna  closed at $27.19, marking a -0.75% move from the previous day. This change lagged the S&P 500's 0.74% gain on the day. On the other hand, the Dow registered a gain of 0.05%, and the technology-centric Nasdaq increased by 1.26%.The biotechnology company's stock has dropped by 14.73% in the past month, falling short of the Medical sector's loss of 7.7% and the S&P 500's loss of 4.77%.Investors will be eagerly watching for the performance of Moderna in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on May 1, 2025. The company's earnings per share  are projected to be -$2.91, reflecting a 5.21% increase from the same quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $126.98 million, down 23.96% from the prior-year quarter.Any recent changes to analyst estimates for Moderna should also be noted by investors. Such recent modifications usually signify the changing landscape of ne","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/moderna-mrna-stock-falls-amid-215014050.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4534","BK4585","BK4501","ISBC","MRNA","BK4551","BK4139","BK4533","BK4211","BK4548","BK4568","BK4532","BK4588"],"gpt_icon":0},{"id":"2530160683","title":"Market Chatter: Novavax Asked by FDA to Run Additional Trial on COVID-19 Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2530160683","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530160683?lang=en_us&edition=fundamental","pubTime":"2025-04-26 04:22","pubTimestamp":1745612571,"startTime":"0","endTime":"0","summary":"Novavax  was asked by the US Food and Drug Administration to run an additional randomized clinical trial on its COVID-19 vaccine, The Wall Street Journal reported Friday, citing people familiar with the matter.That may cost the company tens of millions of dollars, vaccine experts said, according to the report.The vaccine had showed 90% efficacy in a 30,000-person, placebo-controlled trial, the report said.The FDA request allows the company to negotiate for a smaller, less expensive study, the report said, citing a person familiar with the matter.The Department of Health and Human Services and Novavax didn't immediately respond to requests for comment from MT Newswires.Novavax shares fell 1.4% in after-hours trading after dropping 5.7% in the regular session.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4548","BK4585","NVAX","BK4547","BK4139","BK4568","BK4588","BK4535","BNTX","BK4551"],"gpt_icon":1},{"id":"2530916215","title":"BUZZ-Novavax falls after report FDA demands new trial for COVID vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2530916215","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530916215?lang=en_us&edition=fundamental","pubTime":"2025-04-26 03:46","pubTimestamp":1745610377,"startTime":"0","endTime":"0","summary":"BUZZ-Novavax falls after report FDA demands new trial for COVID vaccine** Shares of vaccine maker Novavax NVAX.O fall 6.6% to $6.61 in afternoon trading** US FDA is asking Novavax to conduct an additional clinical trial for its COVID-19 vaccine, despite previous 90% efficacy results, the Wall Street Journal reports, citing people familiar with the matter** The request came after appointees under Health Secretary Robert F. Kennedy Jr. intervened in the approval process - WSJ** Novavax did not immediately respond to a Reuters request for comment** On Wednesday, NVAX said US FDA asked the company to produce more data on its COVID-19 vaccine if it gets full approval** Including session's moves, stock down 12.3% YTD","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nL4N3R31UK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","BK4547","NVAX","BK4568","BK4585"],"gpt_icon":1},{"id":"2530162565","title":"Moderna Shares Lose Ground With Volume Spick in Late Afternoon, Last Down 2%; Pfizer Shares Lose Some Steam, Last up 0.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530162565","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530162565?lang=en_us&edition=fundamental","pubTime":"2025-04-26 03:43","pubTimestamp":1745610181,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nL1N3R312I:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SG9999002232.USD","BK4551","LU0321505868.SGD","LU1023059063.AUD","BK4585","BK4534","BK4139","LU1057294990.SGD","SG9999002224.SGD","BK4007","LU0058720904.USD","BK4548","BK4581","LU0306807586.USD","SG9999011175.SGD","BK4568","LU1066051498.USD","LU0456855351.SGD","BK4533","SG9999003800.SGD","MRNA","LU0321505439.SGD","LU0122379950.USD","LU1894683348.USD","LU0225771236.USD","BK4550","BK4547","BK4532","LU0306806265.USD","NVAX","BK4592","SG9999013999.USD","IE00BBT3K403.USD","SG9999001176.SGD","LU0289739699.SGD","LU1894683264.USD","LU0170899867.USD","LU1066053197.SGD","LU0985481810.HKD","SG9999001176.USD","IE00B19Z3B42.SGD","SGXZ57979304.SGD","IE00BLSP4239.USD","IE0002270589.USD","LU1883839398.USD","IE000M9KFDE8.USD","IE00B19Z3581.USD","PFE","BK4588","IE00BLSP4452.SGD"],"gpt_icon":0},{"id":"2530164423","title":"FDA asks Novavax to complete new clinical trial for delayed COVID-19 shot, WSJ reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2530164423","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530164423?lang=en_us&edition=fundamental","pubTime":"2025-04-26 03:30","pubTimestamp":1745609444,"startTime":"0","endTime":"0","summary":"FDA asks Novavax to complete new clinical trial for delayed COVID-19 shot, WSJ reportsApril 25  - Federal regulators are asking Novavax NVAX.O to complete an additional clinical trial on its Covid-19 vaccine after previously delaying approval, the Wall Street Journal reported on Friday, citing people familiar with the matter.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nL4N3R31U6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BK4585","BK4139","BK4568","BK4588","NVAX"],"gpt_icon":1},{"id":"2530620411","title":"Novavax asked for new Covid-19 vaccine trial by FDA, WSJ reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2530620411","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530620411?lang=en_us&edition=fundamental","pubTime":"2025-04-26 03:30","pubTimestamp":1745609427,"startTime":"0","endTime":"0","summary":"Federal regulators have asked Novavax (NVAX) to conduct another randomized clinical trial of its Covid-19 vaccine following earlier delays in appro...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novavax-asked-for-new-covid-19-vaccine-trial-by-fda-wsj-reports?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novavax-asked-for-new-covid-19-vaccine-trial-by-fda-wsj-reports?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","US3Y.BOND","BK4588","BK4585","US2Y.BOND","US6M.BOND","BK4548","BK4535","US10Y.BOND","BK4547","US12M.BOND","NVAX","BK4551","US30Y.BOND","US5Y.BOND","BNTX","US7Y.BOND","BK4568"],"gpt_icon":0},{"id":"2530167355","title":"Novavax asked by FDA to complete additional COVID trial, WSJ says","url":"https://stock-news.laohu8.com/highlight/detail?id=2530167355","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530167355?lang=en_us&edition=fundamental","pubTime":"2025-04-26 03:25","pubTimestamp":1745609157,"startTime":"0","endTime":"0","summary":"15:23 EDT Novavax (NVAX) asked by FDA to complete additional COVID trial, WSJ says Published first on TheFly – the ultimate source for real-time, m...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novavax-asked-by-fda-to-complete-additional-covid-trial-wsj-says?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novavax-asked-by-fda-to-complete-additional-covid-trial-wsj-says?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4547","NVAX","BK4568","BK4585","BK4588","BK4139"],"gpt_icon":0},{"id":"2530164383","title":"BRIEF-FDA Asks Vaccine Maker Novavax To Complete New Clinical Trial For Delayed Covid-19 Shot - WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2530164383","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530164383?lang=en_us&edition=fundamental","pubTime":"2025-04-26 03:22","pubTimestamp":1745608978,"startTime":"0","endTime":"0","summary":"BRIEF-FDA Asks Vaccine Maker Novavax To Complete New Clinical Trial For Delayed Covid-19 Shot - WSJApril 25 (Reuters) - FDA ASKS VACCINE MAKER NOVAVAX TO COMPLETE NEW CLINICAL TRIAL FOR DELAYED COVID-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nFWN3R32GZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4547","BK4588","BK4139","NVAX","BK4585"],"gpt_icon":0},{"id":"2530841164","title":"FDA Asks Vaccine Maker Novavax to Complete New Clinical Trial for Delayed Covid-19 Shot - WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2530841164","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530841164?lang=en_us&edition=fundamental","pubTime":"2025-04-26 03:21","pubTimestamp":1745608888,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nFWN3R32GZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4585","BK4588","BK4568","BK4547","NVAX"],"gpt_icon":0},{"id":"2530198073","title":"Tariffs Cast a Shadow on Abbott's 2025 View: Time to Sell ABT Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2530198073","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530198073?lang=en_us&edition=fundamental","pubTime":"2025-04-26 03:00","pubTimestamp":1745607600,"startTime":"0","endTime":"0","summary":"Abbott Laboratories ABT has recorded a 15% rise in its share price year to date. Despite the company reporting a solid first-quarter 2025 earnings beat last week, external pressure, particularly the ongoing tariff war, has dampened investors' enthusiasm and capped further market gains. Let's delve deeper.Since its earnings release on April 16, shares of Abbott have edged down 0.2%, underperforming the industry as well as the S&P 500’s gain of 2%. The broader Medical sector collectively gained 1% during this period. The company’s archrivals like Boston Scientific BSX and Medtronic MDT registered share price improvements of 6.2% and 2%, respectively, during the said period.EPD Set for Sustainable Growth: Abbott’s EPD operates solely in emerging geographies, with leading positions in many of the largest and fastest-growing pharmaceutical markets for branded generics in the world. These markets include India, Russia, China and Latin America. Banking on the successful execution of its Brand","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tariffs-cast-shadow-abbotts-2025-190000512.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4566","IE00BJJMRZ35.SGD","LU0072461881.USD","IE00B4R5TH58.HKD","LU1116320901.HKD","LU0162691827.USD","BK4082","LU2133065610.SGD","LU0187121727.USD","LU0496365809.HKD","LU2023251221.USD","LU0048584097.USD","LU0158827948.USD","SMA","ABT","SGXZ23171101.USD","LU1691799644.USD","LU1989771016.USD","LU0234572021.USD","LU0211326755.USD","BK4568","LU2242649171.HKD","LU1116320737.USD","LU2244417387.USD","BK4588","LU0267386448.USD","LU1983299246.USD","LU2265009873.SGD","SG9999004303.SGD","IE00BFTCPJ56.SGD","MDT","BK4585","LU2271345857.HKD","IE0002141913.USD","LU1721429741.USD","LU2089284900.SGD","LU2087625088.SGD","BK4533","LU0823417737.USD","IE0009355771.USD","LU0320765489.SGD","LU0823416689.USD","LU2089283258.USD","BK4217","LU2324357040.USD","BSX","LU1718418525.SGD","LU0976567544.SGD","LU1989772840.SGD","BK4581"],"gpt_icon":0},{"id":"2530625841","title":"Moderna (NasdaqGS:MRNA) Sees 11% Share Price Surge Over Last Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2530625841","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530625841?lang=en_us&edition=fundamental","pubTime":"2025-04-26 01:52","pubTimestamp":1745603532,"startTime":"0","endTime":"0","summary":"Moderna experienced a 10% share price increase, coinciding with broader market gains but slightly below the Nasdaq Composite's 5% rise. Despite the market being uplifted by strong earnings reports and easing tariff concerns, there were no specific events directly attributed to Moderna that week. While broader market trends contributed to the upward momentum, the company's price move was notably larger than the overall market increase of 4%. Such outperformance could have been supported by sustained interest in the biotech sector, even though no significant company-specific announcements were made during the period.View our complete analysis and fair value estimate and you decide.NasdaqGS:MRNA Earnings Per Share Growth as at Apr 2025. Recent market dynamics have driven a sharp increase in Moderna's share price, but the overall narrative around the company remains mixed. While the company's focus on new vaccine development may position it for future revenue diversification, recent news d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/moderna-nasdaqgs-mrna-sees-11-175212463.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4551","BK4568","BK4588","BK4139","BK4532","BK4534","BK4585","MRNA","BK4533","BK4501","BK4548"],"gpt_icon":0},{"id":"2530136072","title":"Gilead Shares Down 3.6% After Quarterly Revenue Miss","url":"https://stock-news.laohu8.com/highlight/detail?id=2530136072","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530136072?lang=en_us&edition=fundamental","pubTime":"2025-04-25 21:32","pubTimestamp":1745587936,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nL4N3R31CJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GILD","IE00B3T34201.USD","IE00B7SZLL34.SGD","LU1571399168.USD","LU1839511570.USD","IE00BZ1G4Q59.USD","LU0320765992.SGD","LU2089984988.USD","LU2468319806.SGD","LU0058720904.USD","BK4583","IE00BSNM7G36.USD","LU0289739699.SGD","BK4550","BK4139","IE00B19Z3B42.SGD","BK4585","BK4566","LU1066051498.USD","BK4578","IE00BKVL7J92.USD","LU0234570918.USD","BK4532","LU2087621335.USD","LU0889565916.HKD","LU1430594728.SGD","LU0109394709.USD","LU1585245621.USD","LU1066053197.SGD","BK4568","IE00B19Z3581.USD","IE0002270589.USD","BK4588"],"gpt_icon":0},{"id":"2530383571","title":"Johnson & Johnson (JNJ) Soared as Markets Favored Defensive Sector","url":"https://stock-news.laohu8.com/highlight/detail?id=2530383571","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530383571?lang=en_us&edition=fundamental","pubTime":"2025-04-25 19:29","pubTimestamp":1745580590,"startTime":"0","endTime":"0","summary":"Mar Vista Investment Partners, LLC, an investment management company, released the “Mar Vista U.S. Quality Select Strategy” first quarter 2025 investor letter.A copy of the letter can be downloaded here. US stocks suffered their worst quarter in three years, with the steepest losses since 2022, due to tariff concerns and economic stagnation fears. In the first quarter, the strategy returned -3.05% net-of-fees compared to -4.49% and -4.27% returns for the Russell 1000 Index and the S&P 500 Index, respectively. Stock selection within healthcare, communication services, and consumer staples detracted from the fund’s performance during the quarter. In addition, please check the fund’s top five holdings to know its best picks in 2025.Mar Vista U.S. Quality Select Strategy stated the following regarding Johnson & Johnson  in its Q1 2025 investor letter:. In another article, we covered Johnson & Johnson  and shared the list of best dividend stocks according to analysts. In addition, please ch","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/johnson-johnson-jnj-soared-markets-112950762.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0345770308.USD","BK4568","LU2347655156.SGD","LU1894683264.USD","IE0009355771.USD","SG9999002232.USD","BK4534","BK4007","IE00B19Z3581.USD","LU1894683348.USD","LU2468319806.SGD","IE0034235303.USD","IE00BVYPNW00.USD","LU0058720904.USD","LU1066051811.HKD","BK4600","LU0795875086.SGD","LU1267930813.SGD","LU1057294990.SGD","LU1929549753.HKD","LU1732800096.USD","IE00BVYPNV92.GBP","LU0114720955.EUR","BK4516","LU2133065610.SGD","LU2112291526.USD","LU0122379950.USD","LU2430703178.SGD","IE00BN8TJ469.HKD","STRK","LU1196500208.SGD","LU1221951046.USD","JNJ","SG9999002224.SGD","BK4532","BK4550","LU1244550221.USD","LU1059921491.USD","LU1261432733.SGD","IE00B4R5TH58.HKD","LU0234572021.USD","LU0203345920.USD","BK4596","LU1778281490.HKD","LU1935042991.SGD","LU2089984988.USD","LU0098860793.USD","LU0795875169.SGD"],"gpt_icon":1},{"id":"2530183726","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2530183726","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530183726?lang=en_us&edition=fundamental","pubTime":"2025-04-25 18:52","pubTimestamp":1745578338,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Gilead Sciences (GILD – Research Report), Merit Medi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-684?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-684?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0002270589.USD","LU0109394709.USD","LU0058720904.USD","BK4566","IE00B7SZLL34.SGD","LU0889565916.HKD","LU2087621335.USD","IE00B19Z3B42.SGD","LU1585245621.USD","GILD","LU1571399168.USD","BK4585","LU1066051498.USD","BK4588","IE00BSNM7G36.USD","LU1066053197.SGD","LU1839511570.USD","BK4568","LU0320765992.SGD","IE00B3T34201.USD","LU2089984988.USD","BK4137","IE00BZ1G4Q59.USD","BK4578","IE00BKVL7J92.USD","BK4550","IE00B19Z3581.USD","HCSG","BK4139","BK4532","BK4583","LU1430594728.SGD","LU2468319806.SGD","LU0234570918.USD","LU0289739699.SGD"],"gpt_icon":0},{"id":"2530903420","title":"Gilead Shares Down 4.2% Premarket After Quarterly Revenue Miss","url":"https://stock-news.laohu8.com/highlight/detail?id=2530903420","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530903420?lang=en_us&edition=fundamental","pubTime":"2025-04-25 17:13","pubTimestamp":1745572426,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nL4N3R30Q8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","LU2087621335.USD","IE00BSNM7G36.USD","IE00BZ1G4Q59.USD","BK4139","LU0058720904.USD","IE00B19Z3581.USD","LU1585245621.USD","LU1066053197.SGD","IE00B7SZLL34.SGD","IE00BKVL7J92.USD","LU1571399168.USD","LU1430594728.SGD","LU0234570918.USD","IE00B19Z3B42.SGD","BK4566","LU0289739699.SGD","LU1839511570.USD","GILD","BK4583","BK4532","LU1066051498.USD","LU2468319806.SGD","IE00B3T34201.USD","IE0002270589.USD","LU0109394709.USD","LU0889565916.HKD","BK4550","LU0320765992.SGD","BK4578","LU2089984988.USD","BK4568","BK4588"],"gpt_icon":0},{"id":"2530527926","title":"Gilead : RBC Raises Target Price to $92 From $89","url":"https://stock-news.laohu8.com/highlight/detail?id=2530527926","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530527926?lang=en_us&edition=fundamental","pubTime":"2025-04-25 13:37","pubTimestamp":1745559472,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nFWN3R301W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GILD","LU2089984988.USD","BK4568","BK4139","LU1571399168.USD","LU2468319806.SGD","IE00B19Z3581.USD","LU0058720904.USD","LU1839511570.USD","LU0109394709.USD","LU2087621335.USD","LU0289739699.SGD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","BK4566","IE00B7SZLL34.SGD","LU0889565916.HKD","LU1430594728.SGD","BK4588","BK4585","IE0002270589.USD","LU0320765992.SGD","LU0234570918.USD","IE00B3T34201.USD","LU1066053197.SGD","LU1585245621.USD","LU1066051498.USD","BK4583","BK4532","BK4550","BK4578"],"gpt_icon":0},{"id":"2530458942","title":"Gilead Sciences (GILD) Gets a Buy from Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2530458942","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530458942?lang=en_us&edition=fundamental","pubTime":"2025-04-25 11:55","pubTimestamp":1745553315,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Matthew Biegler from Oppenheimer maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/gilead-sciences-gild-gets-a-buy-from-oppenheimer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/gilead-sciences-gild-gets-a-buy-from-oppenheimer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4578","BK4532","BK4583","IE00B19Z3581.USD","LU2087621335.USD","IE00B3T34201.USD","LU0058720904.USD","BK4139","IE00BKVL7J92.USD","IE00B19Z3B42.SGD","LU1571399168.USD","BK4588","BK4550","LU0289739699.SGD","LU2468319806.SGD","LU0109394709.USD","BK4566","OPY","BK4585","IE00B7SZLL34.SGD","IE0002270589.USD","BK4127","GILD","LU0889565916.HKD","LU0234570918.USD","LU2089984988.USD","LU1430594728.SGD","BK4568","LU1839511570.USD","LU1066053197.SGD","LU0320765992.SGD","LU1585245621.USD","LU1066051498.USD","IE00BZ1G4Q59.USD","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2530667943","title":"Director Makes Significant Move with Alpha Pro Tech Stock Sale!","url":"https://stock-news.laohu8.com/highlight/detail?id=2530667943","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530667943?lang=en_us&edition=fundamental","pubTime":"2025-04-25 10:03","pubTimestamp":1745546601,"startTime":"0","endTime":"0","summary":"New insider activity at Alpha Pro Tech ( ($APT) ) has taken place on April 25, 2025. Director John Ritota has sold a total of 15,050 shares of Alph...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/director-makes-significant-move-with-alpha-pro-tech-stock-sale?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/director-makes-significant-move-with-alpha-pro-tech-stock-sale?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APT","BK4086","BK4568"],"gpt_icon":0},{"id":"2530491969","title":"Shionogi Raises Year-End Dividend Forecast to 33 Yen","url":"https://stock-news.laohu8.com/highlight/detail?id=2530491969","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530491969?lang=en_us&edition=fundamental","pubTime":"2025-04-25 08:38","pubTimestamp":1745541526,"startTime":"0","endTime":"0","summary":"Shionogi & Co  revised its dividend forecast for the fiscal year ending March 31, 2025, increasing the year-end dividend to 33 yen per share, up from the previous forecast of 29 yen, according to a Thursday filing on the Tokyo Stock Exchange.The company now expects annual dividends of 184 yen per share, an increase of 24 yen from the prior year, reflecting 13 consecutive years of dividend growth.Shionogi's strong performance, driven by the success of its treatments such as Xocova for COVID-19 and Xofluza for influenza, as well as the global expansion of its Cefiderocol sales, contributed to the revision.The company is also advancing its growth phase, particularly with its COVID-19 treatment Ensitrelvir and HIV treatments through its ViiV Healthcare partnership.Price : $2385.00, Change: $-35, Percent Change: -1.43%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","JPY","BK4568","BK4535","BK4548","BK4551","BK4139","BNTX","BK4588"],"gpt_icon":0}],"pageSize":20,"totalPage":14,"pageCount":1,"totalSize":278,"code":"91000000","status":"200"}]}}